Pfizer CentreOne Expands Contract Manufacturing in Japan
Pfizer CentreOne, a contract manufacturing organization embedded within Pfizer, is now offering services in Nagoya, Japan.
The Nagoya site will provide in-country manufacture of highly potent oral solid-dosage forms. It will also provide gateway services into Japan – inspection, packaging, and testing – for highly potent oral solid drugs and sterile injectables made by Pfizer CentreOne outside the country.
The Nagoya facility provides cGMP manufacturing of highly potent oral solid drugs that require containment (to protect personnel from contact with hazardous materials) and segregation (to prevent cross-contamination of drugs in the plant).
The site manufactures: highly active compounds; immunosuppresive drugs; sensitizing agents; and controlled drugs. Dosage forms include: high and multiple doses; combination products; multiple release; and fixed dose.
Source: Pfizer CentreOne